Skip to Content

Avalo Therapeutics Inc AVTX

Morningstar Rating
$21.75 +17.00 (357.89%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

AVTX is trading at a 63% discount.
Price
$4.87
Fair Value
$29.87
Uncertainty
Extreme
1-Star Price
$391.80
5-Star Price
$1.79
Economic Moat
Zssc
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AVTX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$4.75
Day Range
$16.6534.46
52-Week Range
$3.951,130.40
Bid/Ask
$20.20 / $20.21
Market Cap
$17.44 Mil
Volume/Avg
31.9 Mil / 696,441

Key Statistics

Price/Earnings (Normalized)
Price/Sales
0.83
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
20

Valuation

Metric
AVTX
Price/Earnings (Normalized)
Price/Book Value
1.19
Price/Sales
0.83
Price/Cash Flow
Price/Earnings
AVTX

Financial Strength

Metric
AVTX
Quick Ratio
1.95
Current Ratio
2.11
Interest Coverage
−6.46
Quick Ratio
AVTX

Profitability

Metric
AVTX
Return on Assets (Normalized)
−95.17%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
−211.48%
Return on Assets
AVTX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRDkbsjdyrtxSsfm$570.1 Bil
VRTX
Vertex Pharmaceuticals IncKrkshzjgRqkpcxx$108.0 Bil
REGN
Regeneron Pharmaceuticals IncPrbbllvzHtnbm$105.6 Bil
MRNA
Moderna IncChpskgwXbbdk$40.8 Bil
ARGX
argenx SE ADRGdmgpszsPgv$23.7 Bil
BNTX
BioNTech SE ADRXspkxlhzvHgy$21.9 Bil
ALNY
Alnylam Pharmaceuticals IncMxdyrymsgWrrcy$18.8 Bil
BMRN
Biomarin Pharmaceutical IncQjjgbtdsVzptm$16.5 Bil
RPRX
Royalty Pharma PLC Class AXktmxyxsDxyfyq$13.6 Bil
INCY
Incyte CorpZhvhjvsKgsjvj$12.8 Bil

Sponsor Center